Money

Found 79,792 articles

• Drug Farm Raises $27M USD Financing for Advancement of First-In-Class Hepatitis B and Cardiovascular-Renal Drugs into Clinical Trials

  5/16/2023

  Drug Farm, a private biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has raised the first round of C series financing totaling $27 million USD.

• Calliditas Therapeutics: Interim Report Q1, 2023

  5/16/2023

  In March we announced that the global NefIgArd Phase 3 trial successfully met its primary endpoint, estimated glomerular filtration rate, with a p value < 0.0001.

• Coherus Prices Public Offering of Common Stock - May 16, 2023

  5/16/2023

  Coherus BioSciences, Inc. announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share.

• Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast

  5/16/2023

  Beyond Air, Inc., and, through its affiliate Beyond Cancer, Ltd. announced that it will report financial results for its fiscal fourth quarter and year ended March 31, 2023 on Thursday, June 22, 2023.

• NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin

  5/16/2023

  NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission on Monday, May 15, 2023.

• NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

  5/16/2023

  NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2023 and provided a business update.

• Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock

  5/16/2023

  Akero Therapeutics, Inc. announced the pricing of an underwritten offering of 5,238,500 shares of its common stock at a price of $42.00 per share, before deducting underwriting discounts and commissions, for total gross proceeds of approximately $220.0 million.

• Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - May 16, 2023

  5/16/2023

  Annexon, Inc. announced that it has granted equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

• Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023

  5/16/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release first quarter 2023 results and corporate update on Tuesday, May 23, 2023.

• Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update

  5/16/2023

  Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced first quarter results which ended March 31, 2023 and provided a corporate update.

• Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

  5/16/2023

  Sunshine Biopharma Inc. closed its previously announced private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

• ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  5/16/2023

  ANI Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering.

• Quest Diagnostics Declares Quarterly Cash Dividend - May 16, 2023

  5/16/2023

  Quest Diagnostics, the world's leading provider of diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share, payable on July 25, 2023 to shareholders of record of Quest Diagnostics common stock on July 11, 2023.

• Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

  5/16/2023

  Salarius Pharmaceuticals, Inc. announced that it has closed its previously announced private placement for the issuance and sale of an aggregate of 3,636,364 shares of its common stock, Series A-1 warrants to purchase up to an aggregate of 3,636,364 shares of common stock and Series A-2 warrants to purchase up to an aggregate of 3,636,364 shares of common stock at a purchase price of $1.65 per share and accompanying warrants, priced at-the-market under Nasdaq rules.

• StageZero Life Sciences, Ltd Announces Q1 2023 Financial Results - 15.2% Growth in Revenue over Q4 2022 - and Operational Update

  5/16/2023

  StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company"), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions

• 

  Lilly-Backed Nido Biosciences Launches with $109M to Target Neurological Diseases

  5/15/2023

  The precision neuroscience startup has notched $109 million in seed, Series A and B financing as it looks to further develop a Phase I candidate to treat a rare X-linked neuromuscular disorder.

• InspireMD Announces Private Placement of Up to $113.6 Million

  5/15/2023

  InspireMD, Inc. announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional investors that have agreed to provide up to $113.6 million in gross proceeds to InspireMD through a private placement that includes initial upfront funding of $42.2 million.

• Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

  5/15/2023

  Benitec Biopharma Inc., a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference platform, announced financial results for its Third Fiscal Quarter ended March 31, 2023.

• Genelux Corporation Announces $33 Million Private Placement

  5/15/2023

  Genelux Corporation, a late clinical-stage immuno-oncology company, announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share, for gross proceeds of approximately $33 million, before deducting offering expenses payable by Genelux.

• ChomiX Biotech Announces millions of dollars Series Pre-A+ Financing to accelerate the development of Chemoproteomics Platform

  5/15/2023

  ChomiX Biotech Co., Ltd. announced the completion of millions of dollars Pre-A+ Financing by TigerYeah Capital,old shareholder Tsinghua Innovation Ventures, and Morning Spring Venture.